ImpediMed

[ImPoster]

July 23 2013 YE PR - stock up 16% on release.

Key highlights from the quarter:

510(k) clearance received, strengthening the L-Dex U400 franchise in the U.S.

Record number of new customers acquired globally.

Orders from new customers and expanded ordering from key multi-site customers resulted in strong growth in the U.S. lymphoedema revenue quarter over quarter, both compared to same quarter last year and 3rdquarter of financial year 2013.

Continued expansion in Australia and New Zealand through collaboration with 3M and the Australasian Lymphology Association (ALA) resulted in strong revenue growth quarter over quarter, both compared to same quarter last year and 3rd quarter of financial year 2013